硫培南治疗复杂性尿路感染(含肾盂肾炎):一项3期随机试验
住院成人复杂性尿路感染患者随机接受静脉硫培南序贯口服硫培南酯/丙磺舒,或静脉厄他培南序贯口服环丙沙星或阿莫西林-克拉维酸。治疗结束访视(第21天)总体联合临床和微生物学应答率硫培南组67.8% vs 厄他培南组73.9%,未证明非劣效。两种硫培南制剂耐受性良好。
要点
- 硫培南序贯口服方案在第21天总体应答率67.8%,厄他培南序贯方案73.9%,未达非劣效。
- 差异主要由厄他培南组降阶梯至环丙沙星患者无症状性菌尿率较低驱动。
- 静脉和口服硫培南制剂均耐受性良好,与对照方案相当。
核心结论
- 硫培南序贯口服硫培南酯/丙磺舒治疗复杂性尿路感染未证明非劣效于厄他培南序贯口服降阶梯治疗,差异由接受环丙沙星者无症状性菌尿率较低驱动。
- 两种硫培南制剂均耐受性良好。
研究设计与样本
- 3期随机试验,住院成人伴脓尿、菌尿及复杂性尿路感染症状和体征者随机分组。
- 硫培南组:静脉硫培南5天后续口服硫培南酯/丙磺舒;对照组:静脉厄他培南5天后续口服环丙沙星或阿莫西林-克拉维酸,取决于尿路病原体敏感性。
- 主要终点为治疗结束访视(第21天)总体联合临床和微生物学应答。
- 1392例接受治疗患者中,硫培南组444例和厄他培南组440例基线尿培养阳性且符合主要疗效分析。
主要发现
- 产超广谱β-内酰胺酶微生物占26.6%,氟喹诺酮不敏感病原体占38.6%。
- 主要终点总体联合临床和微生物学应答:硫培南组67.8% vs 厄他培南组73.9%(差值-6.1%;95%CI -12.0至-0.1%),未证明非劣效。
- 差异由厄他培南组降阶梯至环丙沙星患者无症状性菌尿率较低驱动。
- 其他时间点总体应答未见实质性差异。
- 静脉和口服硫培南制剂均耐受性良好,与对照方案相当。
临床怎么用
- 作者结论认为硫培南序贯口服硫培南酯/丙磺舒治疗复杂性尿路感染未证明非劣效于厄他培南序贯口服降阶梯治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sulopenem is a thiopenem antibiotic being developed for the treatment of multidrug-resistant infections. The availability of both intravenous (IV) and oral formulations will facilitate earlier hospital discharge. METHODS: Hospitalized adults with pyuria, bacteriuria, and signs and symptoms of complicated urinary tract infection (cUTI) were randomized to 5 days of IV sulopenem followed by oral sulopenem etzadroxil/probenecid or 5 days of IV ertapenem followed by oral ciprofloxacin or amoxicillin-clavulanate, depending on uropathogen susceptibility. The primary end point was overall combined clinical and microbiologic response at the test-of-cure visit (day 21). RESULTS: Of 1392 treated patients, 444 and 440 treated with sulopenem and ertapenem, respectively, had a positive baseline urine culture and were eligible for the primary efficacy analyses. Extended-spectrum β-lactamase-producing organisms were identified in 26.6% of patients and fluoroquinolone-nonsusceptible pathogens in 38.6%. For the primary end point, noninferiority of sulopenem to the comparator regimen was not demonstrated, 67.8% vs 73.9% (difference, -6.1%; 95% confidence interval, -12.0 to -.1%). The difference was driven by a lower rate of asymptomatic bacteriuria in the subgroup of ertapenem-treated patients who stepped down to ciprofloxacin. No substantial difference in overall response was observed at any other time point. Both IV and oral formulations of sulopenem were well-tolerated and compared favorably to the comparator. CONCLUSIONS: Sulopenem followed by oral sulopenem-etzadroxil/probenecid was not noninferior to ertapenem followed by oral step-down therapy for the treatment of cUTIs, driven by a lower rate of asymptomatic bacteriuria in those who received ciprofloxacin. Both formulations of sulopenem were well-tolerated. CLINICAL TRIAL REGISTRATION: NCT03357614.
引用
- Dunne MW, Aronin SI, Das AF, et al. Sulopenem for the Treatment of Complicated Urinary Tract Infections Including Pyelonephritis: A Phase 3, Randomized Trial. Clin Infect Dis. 2023. PMID: 36068705. doi:10.1093/cid/ciac704
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。